NOXAFIL 300 MG CONCENTRATE FOR SOLUTION FOR INFUSION

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

POSACONAZOLE

Commercializzato da:

MERCK SHARP & DOHME ISRAEL LTD

Codice ATC:

J02AC04

Forma farmaceutica:

CONCENTRATE FOR SOLUTION FOR INFUSION

Composizione:

POSACONAZOLE 300 MG/VIAL

Via di somministrazione:

I.V

Tipo di ricetta:

Required

Prodotto da:

MERCK SHARP & DOHME CORP., USA

Area terapeutica:

POSACONAZOLE

Indicazioni terapeutiche:

Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults :- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.- Zygomycosis, in patients intolerant of, or with disease that is refractory to, alternative therapy.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate f

Data dell'autorizzazione:

2017-02-21

Foglio illustrativo

Page 1 of 2
AINF-1254857-0000
יאמ
2018
ה/דבכנ ה/אפור
/חקור
ת
ה/דבכנ :ןודנה ליפסקונ
300
יוריעל הסימת תנכהל תזכורמ הסימת ג"מ
NOXAFIL
 300 MG CONCENTRATE FOR SOLUTION FOR INFUSION (POSACONAZOLE)
DOSAGE FORM: Concentrate for solution for infusion
COMPOSITION: Each vial contains 300 mg of posaconazole.
לארשי םהודו פראש קרמ תרבח
MSD)
ולעה ןוכדע לע עדייל תשקבמ (
ן
לש אפורל ליפסקונ
300 הסימת ג"מ
יוריעל הסימת תנכהל תזכורמ
.
היוותהה ןושל ןלהל
:רישכתל תרשואמה
Noxafil concentrate for solution for infusion is indicated for use in
the treatment of the following
fungal infections in adults (see section 5.1):
-
Invasive aspergillosis in patients with disease that is refractory to
amphotericin B or
itraconazole or in patients who are intolerant of these medicinal
products;
-
Fusariosis in patients with disease that is refractory to amphotericin
B or in patients who are
intolerant of amphotericin B;
-
Chromoblastomycosis and mycetoma in patients with disease that is
refractory to itraconazole
or in patients who are intolerant of itraconazole;
-
Coccidioidomycosis in patients with disease that is refractory to
amphotericin B, itraconazole
or fluconazole or in patients who are intolerant of these medicinal
products.
-
Zygomycosis, in patients intolerant of, or with disease that is
refractory to, alternative therapy.
Refractoriness is defined as progression of infection or failure to
improve after a minimum of 7 days
of prior therapeutic doses of effective antifungal therapy_._
Noxafil concentrate for solution for infusion is also indicated for
prophylaxis of invasive fungal
infections in the following patients:
-
Patients receiving remission-induction chemotherapy for acute
myelogenous leukemia (AML)
or myelodysplastic syndromes (MDS) expected to result in prolonged
neutropenia and who
are at high risk of developing invasive fungal infections;
-
Hematopoi

Scheda tecnica

1.
NAME OF THE MEDICINAL PRODUCT
Noxafil

300 mg concentrate for solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains 300 mg of posaconazole.
Each mL contains 18 mg of posaconazole.
Excipient with known effect:
Each vial contains 462 mg (20 mmol) sodium.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Concentrate for solution for infusion.
Clear, colourless to yellow liquid.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Noxafil concentrate for solution for infusion is indicated for use in
the treatment of the following
fungal infections in adults (see section 5.1):
-
Invasive aspergillosis in patients with disease that is refractory to
amphotericin B or
itraconazole or in patients who are intolerant of these medicinal
products;
-
Fusariosis in patients with disease that is refractory to amphotericin
B or in patients who are
intolerant of amphotericin B;
-
Chromoblastomycosis and mycetoma in patients with disease that is
refractory to itraconazole
or in patients who are intolerant of itraconazole;
-
Coccidioidomycosis in patients with disease that is refractory to
amphotericin B, itraconazole
or fluconazole or in patients who are intolerant of these medicinal
products.
-
Zygomycosis, in patients intolerant of, or with disease that is
refractory to, alternative therapy.
Refractoriness is defined as progression of infection or failure to
improve after a minimum of 7 days
of prior therapeutic doses of effective antifungal therapy
_._
Noxafil concentrate for solution for infusion is also indicated for
prophylaxis of invasive fungal
infections in the following patients:
-
Patients receiving remission-induction chemotherapy for acute
myelogenous leukemia (AML)
or myelodysplastic syndromes (MDS) expected to result in prolonged
neutropenia and who are
at high risk of developing invasive fungal infections;
-
Hematopoietic stem cell transplant (HSCT) recipients who are
undergoing high-dose
immunosuppressive therapy for graft versus host disease (GVHD) and who